• Issue

    Diabetes, Obesity and Metabolism: Volume 22, Issue 12

    2207-2511
    December 2020
Previous Issue|Next Issue
Export Citation(s)

COVER IMAGE

Free Access

Cover Image, Volume 22, Issue 12

Hiroshi Miura,  Kazuhiko Sakaguchi,  Natsu Otowa-Suematsu,  Tomoko Yamada,  Anna So,  Hisako Komada,  Yuko Okada,  Yushi Hirota,  Yoshikazu Tamori,  Wataru Ogawa, 
  • First Published: 17 November 2020
Cover Image, Volume 22, Issue 12 Issue 12, 2020

The cover image is based on the Original Article Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study by Hiroshi Miura et al., https://doi.org/10.1111/dom.14161.

ISSUE INFORMATION

Free Access

Diabetes, Obesity and Metabolism

  • Pages: 2207-2208
  • First Published: 17 November 2020

REVIEW ARTICLES

Open Access

Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results

Kevin M. Pantalone DO,  Kashif Munir MD,  Clinton M. Hasenour PhD,  Charles M. Atisso PhD,  Oralee J. Varnado PhD,  Juan M. Maldonado PharmD,  Manige Konig MD, 
  • Pages: 2209-2226
  • First Published: 03 August 2020
Open Access

A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?

Rebecca K. Vincent MSc,  David M. Williams MSc,  Marc Evans FRCP, 
  • Pages: 2227-2240
  • First Published: 18 September 2020

ORIGINAL ARTICLES

Open Access

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

Simon Heller MD,  Ildiko Lingvay MD,  Steven P. Marso MD,  Athena Philis-Tsimikas MD,  Thomas R. Pieber MD,  Neil R. Poulter FMedSci,  Richard E. Pratley MD,  Elise Hachmann-Nielsen MD,  Kajsa Kvist PhD,  Martin Lange MD,  Alan C. Moses MD,  Marie Trock Andresen MD,  John B. Buse MD,  DEVOTE Study Group , 
  • Pages: 2241-2247
  • First Published: 06 April 2020
Open Access

Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE

Simon Heller MD,  Ildiko Lingvay MD,  Steven P. Marso MD,  Athena Philis-Tsimikas MD,  Thomas R. Pieber MD,  Neil R. Poulter FMedSci,  Richard E. Pratley MD,  Elise Hachmann-Nielsen MD,  Kajsa Kvist PhD,  Martin Lange MD,  Alan C. Moses MD,  Marie Trock Andresen MD,  John B. Buse MD,  DEVOTE Study Group , 
  • Pages: 2248-2256
  • First Published: 30 September 2020

Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study

Dong-Hwa Lee MD,  Eun Ju Chun MD,  Ji Hye Moon RN,  Han Mi Yun BS,  Soo Lim MD, 
  • Pages: 2257-2266
  • First Published: 22 July 2020

The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies

Silvina Gallo,  Annaswamy Raji,  Roberto A. Calle,  Annpey Pong,  Christian Meyer, 
  • Pages: 2267-2275
  • First Published: 22 July 2020

Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies

Richard Pratley MD,  Samuel Dagogo-Jack MD,  Bernard Charbonnel MD,  Shrita Patel MD,  Anne Hickman DVM,  Jie Liu MD,  Lisa Tarasenko PharmD,  Annpey Pong PhD,  Misoo C. Ellison PhD,  Susan Huyck DrPH,  Ira Gantz MD,  Steven G. Terra PharmD, 
  • Pages: 2276-2286
  • First Published: 23 July 2020

Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study

Muhammad Abdul-Ghani MD,  Osama Migahid MD,  Ayman Megahed MD,  Ralph A. DeFronzo MD,  Ebaa Al-Ozairi MD,  Amin Jayyousi MD, 
  • Pages: 2287-2294
  • First Published: 30 July 2020
Open Access

Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists

Julio Rosenstock MD,  Francisco Javier Ampudia-Blasco MD,  Robert Lubwama DDS,  Xuejun Victor Peng MD,  Anders Boss MD,  Lizheng Shi MD,  Vivian Fonseca MD, 
  • Pages: 2295-2304
  • First Published: 30 July 2020

Genetic variation in lean body mass, changes of appetite and weight loss in response to diet interventions: The POUNDS Lost trial

Xiang Li MD, PhD,  Tao Zhou PhD,  Hao Ma PhD,  Yoriko Heianza RD, PhD,  Catherine M. Champagne PhD,  Donald A. Williamson PhD,  George A. Bray MD,  Frank M. Sacks MD,  Lu Qi MD, PhD, 
  • Pages: 2305-2315
  • First Published: 30 July 2020

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li PhD,  Xiaoxue Zhu MS,  Jingrui Liu MS,  Qianqian Li MS,  Hong Zhang MD,  Cuiyun Li MS,  Min Wu MS,  Lei Gao MS,  He Wen PhD,  Xixi Li BS,  Xinran Tang MS,  Li Liu MD,  Yanhua Ding MD, 
  • Pages: 2316-2324
  • First Published: 03 August 2020

Associations between usual glycated haemoglobin and cardiovascular disease in patients with type 2 diabetes mellitus: A 10-year diabetes cohort study

Eric YF Wan PhD,  Esther YT Yu MBBS,  Julie Y Chen MD,  Ian CK Wong PhD,  Esther WY Chan PhD,  Cindy LK Lam MD, 
  • Pages: 2325-2334
  • First Published: 03 August 2020
Open Access

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial

Christoph Wanner MD,  Silvio E. Inzucchi MD,  Bernard Zinman MD,  Audrey Koitka-Weber PhD,  Michaela Mattheus Dipl Biomath,  Jyothis T. George MD,  Maximilian von Eynatten MD,  Sibylle J. Hauske MD,  EMPA-REG OUTCOME Investigators , 
  • Pages: 2335-2347
  • First Published: 03 August 2020

Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals

Chen-Yu Huang MD,  Jen-Kuang Lee MD, PhD, 
  • Pages: 2348-2355
  • First Published: 03 August 2020

Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study

Hiroshi Miura,  Kazuhiko Sakaguchi,  Natsu Otowa-Suematsu,  Tomoko Yamada,  Anna So,  Hisako Komada,  Yuko Okada,  Yushi Hirota,  Yoshikazu Tamori,  Wataru Ogawa, 
  • Pages: 2356-2363
  • First Published: 03 August 2020

Assessing the cost-effectiveness of sodium–glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence

Phil McEwan PhD,  Hayley Bennett MSc,  Kamlesh Khunti FAMedSci,  John Wilding DM,  Christopher Edmonds,  Marcus Thuresson PhD,  Eric Wittbrodt PharmD,  Peter Fenici MD,  Mikhail Kosiborod MD, 
  • Pages: 2364-2374
  • First Published: 03 August 2020

Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial

Fei Gao PhD,  Xiaofeng Lv Prof.,  Zhaohui Mo Prof.,  Jianhua Ma Prof.,  Qiu Zhang Prof.,  Gangyi Yang Prof.,  Weijuan Liu MD,  Quanmin Li Prof.,  Jian Zhou Prof.,  Yuqian Bao Prof.,  Weiping Jia Prof., 
  • Pages: 2375-2383
  • First Published: 03 August 2020

Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study

Olga Montvida PhD,  Subodh Verma MD, PhD,  Jonathan E. Shaw MD, PhD,  Sanjoy K. Paul PhD, 
  • Pages: 2384-2397
  • First Published: 03 August 2020

The effect of a low glycaemic index diet on reducing day-long glycaemia in healthy young adults: A randomized crossover trial

Hannah Wing Han Hon BSc,  Tommy Hon Ting Wong MNutrDiet,  Iris Mei Ying Tse BSc,  Jimmy Chun Yu Louie PhD, 
  • Pages: 2398-2407
  • First Published: 05 August 2020

Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study

Luigi E. Adinolfi MD,  Salvatore Petta MD,  Anna L. Fracanzani MD,  Riccardo Nevola MD,  Carmine Coppola MD,  Vincenzo Narciso MD,  Luca Rinaldi MD,  Vincenza Calvaruso MD,  Pia Clara Pafundi MSc,  Rosa Lombardi MD,  Laura Staiano MD,  Vito Di Marco MD,  Antonio Solano MD,  Aldo Marrone MD,  Mariarosaria Saturnino MD,  Francesca Rini MD,  Barbara Guerrera MD,  Graziano Troina MD,  Mauro Giordano MD,  Antonio Craxì MD,  Ferdinando C. Sasso MD, 
  • Pages: 2408-2416
  • First Published: 05 August 2020
Open Access

Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

Francesco Zaccardi PhD,  Emmanuelle Jacquot MD,  Viviana Cortese MD,  Freya Tyrer MSc,  Samuel Seidu MD,  Melanie J. Davies MD,  Kamlesh Khunti PhD, 
  • Pages: 2417-2426
  • First Published: 05 August 2020
Open Access

Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes

Namam Ali MD,  Anna W. M. Janssen MD,  Martin Jaeger PhD,  Lisa Van de Wijer MSc,  Wouter van der Heijden MSc,  Rob ter Horst MSc,  Priya Vart PhD,  Alain van Gool PhD,  Leo A. B. Joosten PhD,  Mihai G. Netea MD,  Rinke Stienstra PhD,  Bastiaan E. De Galan MD,  Cees J. Tack MD, 
  • Pages: 2427-2436
  • First Published: 16 August 2020

Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists

Wenyu Li MS,  Thomas Kirchner BS,  George Ho MS,  Fany Bonilla MS,  Katharine D'Aquino PhD,  James Littrell BS,  Rui Zhang PhD,  Wenying Jian PhD,  Xi Qiu PhD,  Songmao Zheng PhD,  Bin Gao PhD,  Peggy Wong PhD,  James N. Leonard PhD,  Raul C. Camacho PhD, 
  • Pages: 2437-2450
  • First Published: 16 August 2020
Open Access

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Jonathan M. Wilson PhD,  Amir Nikooienejad PhD,  Deborah A. Robins MS,  William C. Roell PhD,  Jeffrey S. Riesmeyer MD,  Axel Haupt MD,  Kevin L. Duffin PhD,  Marja-Riitta Taskinen MD,  Giacomo Ruotolo MD, 
  • Pages: 2451-2459
  • First Published: 16 August 2020
Open Access

Dietary fibre intake in childhood or adolescence and subsequent health outcomes: A systematic review of prospective observational studies

Andrew N. Reynolds,  Huyen Tran Diep Pham,  Jason Montez PhD,  Jim Mann PhD, 
  • Pages: 2460-2467
  • First Published: 26 August 2020

Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation

Neil Tanday PhD,  Nigel Irwin PhD,  R. Charlotte Moffett PhD,  Peter R. Flatt PhD,  Finbarr P. M. O'Harte PhD, 
  • Pages: 2468-2478
  • First Published: 26 August 2020
Open Access

Machine-learning–based early prediction of end-stage renal disease in patients with diabetic kidney disease using clinical trials data

Sunil Belur Nagaraj PhD,  Michelle J. Pena PhD,  Wenjun Ju PhD,  Hiddo L. Heerspink PhD,  The BEAt-DKD Consortium , 
  • Pages: 2479-2486
  • First Published: 26 August 2020

BRIEF REPORTS

Open Access

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

Subodh Verma MD,  Darren K. McGuire MD,  Stephen C. Bain MD,  Deepak L. Bhatt MD,  Lawrence A. Leiter MD,  C. David Mazer MD,  Tea Monk Fries MD,  Richard E. Pratley MD,  Søren Rasmussen PhD,  Hrvoje Vrazic MD,  Bernard Zinman MD,  John B. Buse MD, 
  • Pages: 2487-2492
  • First Published: 03 August 2020
Open Access

Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial

Annemarie B. van der Aart-van der Beek PharmD,  Lindsay E. Clegg PhD,  Robert C. Penland PhD,  David W. Boulton PhD,  C. David Sjöström MD,  Robert J. Mentz MD,  Rury R. Holman FRCP,  Hiddo J. L. Heerspink PhD, 
  • Pages: 2493-2498
  • First Published: 17 August 2020

Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety

Nga N. Nguyen BS,  Irina Kolobova PhD,  Bruce M. Wolfe MD,  Jonathan Q. Purnell MD, 
  • Pages: 2499-2503
  • First Published: 01 September 2020

LETTERS TO THE EDITOR

Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying

Michael Horowitz PhD,  Christopher K. Rayner PhD,  Chinmay S. Marathe PhD,  Tongzhi Wu PhD,  Karen L. Jones PhD, 
  • Pages: 2504-2506
  • First Published: 04 August 2020

COVID-19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them?

Sandro Gentile MD,  Felice Strollo MD,  Andrea Mambro MD,  Antonio Ceriello MD, 
  • Pages: 2507-2508
  • First Published: 13 August 2020

Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?

Galyna V. Graham PhD,  Chris M. McLaughlin PhD,  Peter R. Flatt DSc, 
  • Pages: 2509-2511
  • First Published: 16 August 2020